Replies to post #173586 on Biotech Values

[DewDiligence]

Once-daily dosing is a far bigger advantage for GILD than Dew and you seem to think.

You’ve neglected to realize that GILD’s Sovaldi + Ledipasvir regimen is de facto BID dosing for any subgroup in which ribavirin is used.

[GrthzGd]

This board covers many companies, and there isn't room for ad hominem attacks nor for redundancies, as noted in our moderator's comment to you. I'll therefore limit my response to the observation that you should be more careful in your choice of words. If you haven't sold ENTA, you're not "willing to wager" as to the strength of your argument.

[DewDiligence]

That kind of knee-jerk reductionist thinking, unfortunately, is all-to-prevalent on this board, IMO.

I doubt you can back that up with concrete examples other than tokens.

p.s. You haven’t responded to my critiques of your arguments such as the one in #msg-96654188.

p.p.s. When you are hunting for information, you are fond of proclaiming that you are the “dumbest” biotech investor on this board (which, of course, is far from accurate). However, when you want to make a point, you often do so stridently, as though the people on the other side of the debate were imbeciles. I would submit that your dual personas are in conflict and you ought to drop the “dumb” shtick.